| An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR–dependent pathway D Guo, F Reinitz, M Youssef, C Hong, D Nathanson, D Akhavan, D Kuga, ... Cancer discovery 1 (5), 442-456, 2011 | 448 | 2011 |
| mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc K Masui, K Tanaka, D Akhavan, I Babic, B Gini, T Matsutani, A Iwanami, ... Cell metabolism 18 (5), 726-739, 2013 | 408 | 2013 |
| EGFR signaling through an Akt-SREBP-1–dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy D Guo, RM Prins, J Dang, D Kuga, A Iwanami, H Soto, KY Lin, TT Huang, ... Science signaling 2 (101), ra82-ra82, 2009 | 362 | 2009 |
| Oncogenic EGFR signaling activates an mTORC2–NF-κB pathway that promotes chemotherapy resistance K Tanaka, I Babic, D Nathanson, D Akhavan, D Guo, B Gini, J Dang, ... Cancer discovery 1 (6), 524-538, 2011 | 332 | 2011 |
| The channel architecture of aquaporin 0 at a 2.2-Å resolution WEC Harries, D Akhavan, LJW Miercke, S Khademi, RM Stroud Proceedings of the National Academy of Sciences 101 (39), 14045-14050, 2004 | 327 | 2004 |
| mTOR signaling in glioblastoma: lessons learned from bench to bedside D Akhavan, TF Cloughesy, PS Mischel Neuro-oncology 12 (8), 882-889, 2010 | 216 | 2010 |
| An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity KJ Williams, JP Argus, Y Zhu, MQ Wilks, BN Marbois, AG York, Y Kidani, ... Cancer research 73 (9), 2850-2862, 2013 | 195 | 2013 |
| CAR T cells for brain tumors: Lessons learned and road ahead D Akhavan, D Alizadeh, D Wang, MR Weist, JK Shepphird, CE Brown Immunological reviews 290 (1), 60-84, 2019 | 189 | 2019 |
| EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer I Babic, ES Anderson, K Tanaka, D Guo, K Masui, B Li, S Zhu, Y Gu, ... Cell metabolism 17 (6), 1000-1008, 2013 | 170 | 2013 |
| De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients D Akhavan, AL Pourzia, AA Nourian, KJ Williams, D Nathanson, I Babic, ... Cancer discovery 3 (5), 534-547, 2013 | 147 | 2013 |
| Glycerol facilitator GlpF and the associated aquaporin family of channels RM Stroud, LJW Miercke, J O’Connell, S Khademi, JK Lee, J Remis, ... Current opinion in structural biology 13 (4), 424-431, 2003 | 105 | 2003 |
| Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism AN Cvrljevic, D Akhavan, M Wu, P Martinello, FB Furnari, AJ Johnston, ... Journal of cell science 124 (17), 2938-2950, 2011 | 59 | 2011 |
| The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas B Gini, C Zanca, D Guo, T Matsutani, K Masui, S Ikegami, H Yang, ... Clinical Cancer Research 19 (20), 5722-5732, 2013 | 56 | 2013 |
| Pilot study on “pericytic mimicry” and potential embryonic/stem cell properties of angiotropic melanoma cells interacting with the abluminal vascular surface C Lugassy, M Wadehra, X Li, M Corselli, D Akhavan, SW Binder, B Péault, ... Cancer Microenvironment 6, 19-29, 2013 | 56 | 2013 |
| Shifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases A Shinde, D Akhavan, M Sedrak, S Glaser, A Amini CNS oncology 8 (1), CNS27, 2019 | 31 | 2019 |
| De novo design of an IL-4 antagonist and its structure at 1.9 Å SL LaPorte, CM Forsyth, BC Cunningham, LJ Miercke, D Akhavan, ... Proceedings of the National Academy of Sciences 102 (6), 1889-1894, 2005 | 31 | 2005 |
| De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013; 3: 534–547. doi: 10.1158 … D Akhavan, AL Pourzia, AA Nourian, KJ Williams, D Nathanson, I Babic, ... DOI: https://doi. org/10.1158/2159-8290. CD-12-0502. PMID: https://www. ncbi …, 0 | 30 | |
| The effects of time to treatment initiation for patients with non–small-cell lung cancer in the United States TR Cushman, B Jones, D Akhavan, CG Rusthoven, V Verma, R Salgia, ... Clinical lung cancer 22 (1), e84-e97, 2021 | 28 | 2021 |
| Phase I study of yttrium-90 radiolabeled M5A anti-carcinoembryonic antigen humanized antibody in patients with advanced carcinoembryonic antigen producing malignancies D Akhavan, P Yazaki, D Yamauchi, J Simpson, PH Frankel, J Bading, ... Cancer Biotherapy & Radiopharmaceuticals 35 (1), 10-15, 2020 | 15 | 2020 |
| Final Report–Feasibility study for establishment of air ventilation assessment system E Ng, I Tam, A Ng, B Givoni, L Katzschner, K Kwok, S Murakami, ... Technical Report for Planning Department HKSAR, 2004 | 15 | 2004 |
